[ad_1]
Gothenburg, Sweden / ACCESSWIRE / February 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 29, 2024 – IRLAB Therapeutics AB (NASDAQ Stockholm: IRLAB A) is a company discovering and developing new treatments for Parkinson’s disease. ) today announced that the company: will be presenting at the event Life Science-dagen in Gothenburg on March 6th. The company will also participate in his Fireside Chat with ABG, which will be published on March 6th.
At Life Science-dagen, IRLAB’s CFO Viktor Siewertz will give a 20-minute presentation about the company, followed by a 10-minute Q&A from 09:15 to 09:45. The event will be held at the Wallenberg Conference Center at He Medicinaregatan 20 in Gothenburg. The event will be live-streamed and will be available to watch on the event website after the event.
For more information, please visit www.lifesciencedagen.se.
The ABG-hosted fireside chat will be a conversation between IRLAB CFO Viktor Siewertz and ABG analysts. The conversation will be recorded and made available on ABG’s contract research website until March 6, 2024.
For fireside chats and other IRLAB-related content, visit https://cr.abgsc.com/foretag/irlab-therapeutics/Media/.
For more information
Victor Siewerts, CFO
Phone: +46 727 10 70 70
Email: viktor.siewertz@irlab.se
About IRLAB
IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson’s disease. The company’s origins lie in the research group of Nobel Prize winner Professor Arvid Karlsson and his discovery of the link between brain neurotransmitters and CNS diseases. Mesdopetam (IRL790), which is being developed for the treatment of levodopa-induced dyskinesia, has completed Phase IIb and is preparing for Phase III. Pirepemat (IRL752) is currently in Phase IIb and is being evaluated for its effects on balance and fall frequency in Parkinson’s disease. Additionally, the company is advancing his three preclinical programs, IRL757 (funded by the Michael J. Fox Foundation), IRL942, and his IRL1117, toward Phase I trials. IRLAB’s pipeline was generated by the company’s proprietary systems biology-based Integrated Screening Process (ISP) research platform. Headquartered in Sweden, his IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.
attachment
IRLAB will speak at Life Science-dagen in Gothenburg and have a hearth conversation with ABG
sauce: IRLAB Therapeutics
View the original press release at accesswire.com
[ad_2]
Source link
